DUXAP8 and hepatocellular carcinoma: found that overexpression of LINC DUXAP8 in hepatocellular carcinoma cells could enhance the action of SLC7A11 by promoting palmitoylation of the XC-subunit SLC7A11 and preventing its lysosomal degradation, which in turn inhibited ferroptosis and enhanced the resistance of advanced hepatocellular carcinoma cells to sorafenib (56).